Clinical Trial Detail

NCT ID NCT04157517
Title A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics Study
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

lung non-small cell carcinoma

prostate cancer

Advanced Solid Tumor

Therapies

TAK-573

Age Groups: adult senior

No variant requirements are available.